CV6 Therapeutics Inc., CEO and Founder, Dr Robert Ladner will be attending JP Morgan Week, to be held on the 8th-12th January at the Marriott Marquis in San Francisco, California, USA. CV6 Therapeutics is a drug development company focussed on developing value-based, first-in-class medications that are scalable to address global unmet medical needs.
JP Morgan week will see leading minds in pharma and healthcare gather to discuss evolving deal dynamics, regulatory insights, treatment breakthroughs, and strategic AI deployment, addressing pressing issues and exciting opportunities in the life sciences industry.
Dr Ladner, who will be in attendance for the duration of the event said, “JP Morgan Week represents a unique opportunity to meet and build relationships with the foremost leaders in biotech, pharma and financing. These partnerships are critical in advancing CV6 Therapeutics to the next level in our strategic vision.”
CV6 Therapeutics’ first oncology clinical candidate, CV6-168, received MHRA approval to enter a first-in-human phase 1a trial in early 2024. CV6-168 is a first-in-class DNA uracilation agent that specifically targets the enzyme dUTPase. Inhibition of dUTPase in combination with thymidylate synthase (TS) inhibitors (e.g., 5-FU and pemetrexed) causes the misincorporation of uracil into DNA during cancer cell replication inducing DNA damage, potent activation of the innate immune system, and cancer cell death.
Dr Ladner will be available to discuss the clinical strategy for CV6-168 and upcoming financing requirements for the Phase 1b clinical trial. Meetings can be arranged via the JP Morgan Week One-on-One BioPartnering’ hub here:
or by email to email@example.com
CV6 Therapeutics is developing value-based, first-in-class medications that are scalable to address global unmet medical needs in the oncology and inflammatory disease markets. To learn more about CV6 Therapeutics and its product pipeline including CV6-168, or to contact us, click here: http://www.cv6t.com